One System. Infinite Parameters.
Configure, explore, and translate LIFU research — all on a single modular platform.
Designed for discovery and built for translation
Open-LIFU gives researchers a configurable platform to investigate the full range of low-intensity focused ultrasound effects and therapies. Its modular medical device architecture means every component — from transducer arrays to control software — can be tailored to the demands of your research, whether you're mapping acoustic fields, optimizing treatment parameters, or exploring new therapeutic targets.
But Open-LIFU isn't just a lab tool. The same modular design that makes it endlessly adaptable at the bench also makes it a credible path to the clinic. Researchers can move from exploratory studies to translational work on a single, continuous platform — reducing the friction that so often stalls promising science between discovery and patient care.
TRANSCRANIAL FUS
Transcranial focused ultrasound (tFUS) is a non-invasive brain stimulation technology that uses precisely targeted acoustic waves to modulate neural activity deep within the brain — without surgery, radiation, or electrodes.
Unlike older neurostimulation methods, tFUS can reach subcortical structures with millimeter-level spatial precision, opening doors that techniques like TMS and tDCS simply can't.
tFUS represents a convergence of neuroscience, acoustics, and medical engineering — and it's rapidly moving from the research lab into clinical trials worldwide.
-
Applications
Neurological & Psychiatric Treatment
tFUS is being explored as a therapeutic tool for depression, OCD, chronic pain, epilepsy, and essential tremor — conditions where precise modulation of specific circuits may relieve symptoms that drugs can't fully address.
Cognitive & Sensory ResearchResearchers use tFUS to temporarily and safely disrupt or enhance activity in targeted regions, building a clearer map of how different brain areas contribute to memory, attention, perception, and decision-making.
Drug DeliveryCombined with microbubbles, focused ultrasound can transiently open the blood-brain barrier at a chosen site — enabling targeted delivery of therapeutics that would otherwise be blocked.
Intraoperative & Diagnostic UsetFUS shows promise as a real-time monitoring and intervention tool during neurosurgical procedures, and may help identify dysfunctional tissue with greater precision than current imaging alone.
-
tFUS Publications
Neurological and Psychiatric Treatment:
The Brain’s Last Barrier —
and How Low-Intensity Focused Ultrasound Can Open It
Low-intensity focused ultrasound · Microbubbles · Targeted drug delivery
The blood-brain barrier is one of the body’s most sophisticated defense systems. A dense network of tightly packed cells lining the brain’s blood vessels, it shields neural tissue from pathogens, toxins, and foreign molecules — including most therapeutic drugs.
For decades, this barrier has been medicine’s most frustrating obstacle. Treatments that work elsewhere in the body simply can’t reach the brain in meaningful concentrations. Systemic drug flooding, surgical implants, and chemical workarounds have all fallen short — either too imprecise, too invasive, or too risky.
Low-intensity focused ultrasound (LIFU), combined with microbubbles, changes the equation entirely.
Microbubbles are microscopic gas-filled spheres — smaller than a red blood cell — injected into the bloodstream before treatment. When focused ultrasound reaches them at the target site, they oscillate rapidly, gently massaging the vessel walls and loosening the tight junctions of the blood-brain barrier at precisely the right location. The effect is highly localized, controllable, and amplified — microbubbles allow the barrier to open at significantly lower acoustic energy levels than ultrasound alone, reducing stress on surrounding tissue.
The window opens. The drug passes through. Then the barrier closes again, naturally, within hours.
No incisions. No systemic toxicity. No permanent disruption.
The result is a delivery mechanism that is simultaneously more targeted than any surgical approach and less invasive than a standard infusion — opening new possibilities for treating brain tumors, Alzheimer’s disease, Parkinson’s disease, epilepsy, and beyond.
Brain tumors · Alzheimer’s disease · Parkinson’s disease · Epilepsy
.png)
microbubbles
junctions
molecules
-
Relevant Publications
Pharmaceutics · 2025
What happens after the door opens?
Arsiwala et al. · West Virginia University
Opening the blood-brain barrier is only half the story — what happens next matters just as much. This study found that a single session of low-intensity focused ultrasound (LiFUS) doesn’t create just one window of opportunity: it triggers a two-phase opening of the barrier over time. Researchers tracked downstream effects on drug transporter proteins and inflammation in both treated and untreated brain regions, offering a clearer roadmap for timing drug delivery after ultrasound treatment — a critical step toward making this technology clinically precise.
Read full article →
Journal of Neuro-Oncology · 2024
Unlocking glioblastoma: what the clinical trials tell us
Zhu et al. · King’s College London
Glioblastoma is one of the deadliest brain cancers — and the blood-brain barrier is a major reason treatments fail. This systematic review examined clinical trials using focused ultrasound combined with microbubbles to temporarily breach that barrier and boost drug delivery directly to tumors. The approach proved non-invasive, targeted, and reversible, with microbubbles amplifying the ultrasound effect at the barrier wall. The review maps where the evidence is strongest, where gaps remain, and what the field needs to push toward broader clinical use.
Read full article →
Neuro-Oncology · 2024
Beyond ultrasound alone: a consensus on breaking the barrier
Piper et al. · Moffitt Cancer Center
A multidisciplinary team reviewed the full landscape of strategies designed to get drugs past the blood-brain barrier in CNS tumor patients. Among emerging technologies, low-intensity focused ultrasound stood out for its ability to temporarily and safely increase barrier permeability — no surgery required. While most LIFU advances are still in animal models, the authors highlight a growing pipeline of translational clinical trials expected to report results in the coming years, signaling that a tipping point in clinical adoption may be near.
Read full article →
Learn More Today